DCTH Share Price

Open 1.98 Change Price %
High 1.98 1 Day -0.10 -5.00
Low 1.85 1 Week -0.37 -16.30
Close 1.90 1 Month 0.14 7.95
Volume 94242 1 Year 1.46 331.82
52 Week High 6.49
52 Week Low 0.22
DCTH Important Levels
Resistance 2 2.02
Resistance 1 1.97
Pivot 1.91
Support 1 1.83
Support 2 1.78
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
DVOX 0.05 -44.44%
More..

Delcath Systems, Inc. (NASDAQ: DCTH)

DCTH Technical Analysis 2
As on 2nd Dec 2016 DCTH Share Price closed @ 1.90 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.43 & Strong Sell for SHORT-TERM with Stoploss of 2.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
DCTH Target for December
1st Target up-side 3.14
2nd Target up-side 3.87
3rd Target up-side 4.6
1st Target down-side 1.04
2nd Target down-side 0.31
3rd Target down-side -0.42
DCTH Other Details
Segment EQ
Market Capital 112475016.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.delcath.com
DCTH Address
DCTH
810 Seventh Avenue
35th Floor
New York, NY 10019
United States
Phone: 212-489-2100
Fax: 212-489-2102
DCTH Latest News
Interactive Technical Analysis Chart Delcath Systems, Inc. ( DCTH NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Delcath Systems, Inc.
DCTH Business Profile
Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).